Recently, the case of tfboys captain Wang Junkai suing Zhendong Pharmaceutical, a well-known A-share pharmaceutical giant, has attracted attention.
Picture source: Wang Junkai's studio Weibo
Public information shows that Wang Junkai was born in Chongqing on September 21, 1999. He is a film and television actor in Mainland China, a pop singer, and the captain of the men's singing group tfboys; he graduated from Beijing Film Academy with the 2017 performance class He is an undergraduate student and has starred in film and television works such as "The Worry-Relief Grocery Store", "Gateway to Rebirth" and "Ten Thousand Miles Home".
Wang Junkai sued Zhendong Pharmaceutical for infringement of portrait rights
The company responded: The store photoshopped the photos themselves
Recently, the China Trial Publicity Network released a trial notice. The cause of the case was a dispute over portrait rights. The plaintiff was Wang Junkai and the defendant was Guizhou Yipin Pharmaceutical Chain Co., Ltd. No. 501 Branch, Shanxi Zhendong Anxin Biopharmaceutical Co., Ltd., Shanxi Zhendong Pharmaceutical Co., Ltd., Xiajiang. The case will be heard in the Baiyun District People's Court of Guiyang City on the morning of January 8.
Among the above defendants, Shanxi Zhendong Pharmaceutical Co., Ltd. is an A-share listed company Zhendong Pharmaceutical (300158), and Shanxi Zhendong Anxin Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of Zhendong Pharmaceutical. The 501th branch of Guizhou Yipin Pharmaceutical Chain Co., Ltd., which is also in the defendant's seat in this case, was established in 2020. The person in charge is Xia Jiang, who is the chairman, general manager and actual controller of Guizhou Yipin Pharmaceutical Chain Co., Ltd. .
Zhendong Pharmaceutical is a subsidiary of Zhendong Group (Shanxi Zhendong Health Industry Group Co., Ltd.). According to the official website information, Zhendong Group was founded on October 1, 1993, starting from oil trading; it transformed into pharmaceuticals in 2002, and became the first GEM listed company in Shanxi Province in 8 years. Zhendong Group covers four major sectors: "Chinese and Western pharmaceuticals, health functional foods, health care products, and Chinese medicinal material cultivation", including Changzhi Zhendong, Datong Taisheng, Tunliu Wuhetang, Taiyuan Anxin, Chinese medicinal material development, decoction piece technology, Wuhe Medical It has 8 major industrial enterprises including health care and health care, with 32 subsidiaries and 3 major R&D platforms. Its food safety has passed the international haccp certification, and its product testing has passed the international cnas certification (the test results of drugs, health functional foods, and Chinese medicinal materials are internationally recognized ) health industry group with total assets of 13.7 billion yuan.
It is reported that the company owns Dafeixin, an anti-hair loss and hair growth brand. The industry speculates that this infringement may be related to this product.
According to Beijing Business Daily, in response to this infringement, the reporter contacted the relevant person in charge of Zhendong Pharmaceutical. The other party said that the company’s advertisements have been reviewed. This incident was caused by a store (Guizhou Yipin Pharmaceutical Chain Co., Ltd. 501 Branch ) edited a picture by myself.
Zhang Wenbo, senior partner of Beijing Jundu Law Firm and director of the Life Sciences and Healthcare Legal Department, said that generally speaking, such cases will be settled. If the 501 branch of Guizhou Yipin Pharmaceutical Chain Co., Ltd. has independent business qualifications, Zhendong Pharmaceutical has no joint infringement intention and does not need to pay compensation.
5.8 billion sale of "China's Calcium King"
Performance plummeted after transforming into "hair loss economy"
In 2021, Zhendong Pharmaceutical sold Langdi, known as "China's Calcium King", and transformed into hair loss, causing a wave of turmoil in the capital market. However, by 2022, Zhendong Pharmaceutical began to suffer losses. In the first three quarters of 2023, the company achieved operating income of 2.784 billion yuan, a year-on-year decrease of 0.55%; net profit attributable to the parent company was -874,200 yuan, a year-on-year decrease of 103.53%; in the third quarter, the company achieved operating income of 851 million yuan, and net profit attributable to the parent company was -1541.66 million, down 20.74% and 15654.59% respectively year-on-year.
In 2016, Zhendong Pharmaceutical spent 2.646 billion yuan to acquire 100% of the equity of Kangyuan Pharmaceutical (later renamed "Langdi Pharmaceutical"). Since then, its performance has increased steadily, and the two companies have achieved a "win-win" - in 2020, Zhendong Pharmaceutical achieved Operating income was 4.848 billion yuan, and net profit attributable to the parent company was 262 million yuan, of which Langdi Pharmaceutical’s contribution was 750 million yuan and 361 million yuan respectively; Zhendong Pharmaceutical’s “2019 General Manager Work Report” mentioned that “In 2019, carbonated Calcium d3 occupies 65% of the national pharmacy sales market, far ahead of other similar products, and terminal sales increased by 21.2% year-on-year."
However, with Zhendong Pharmaceutical’s statement of “focusing on the medical beauty market, deepening the field of oncology, reducing diversified development, and implementing strategic slimming”, Langdi Pharmaceutical can only become independent. On August 17, 2021, Zhendong Pharmaceutical plans to invest 5.8 billion yuan 100% equity interest in Langdi Pharmaceutical was sold at a price of .
Beginning in 2021, Zhendong Pharmaceutical turned to the "hair loss economy" and began to vigorously promote anti-hair loss products. At present, Zhendong Pharmaceutical's main anti-hair loss product is Dafuxin minoxidil liniment for the treatment of androgenic alopecia and alopecia areata. The sales of this product in 2021 and 2022 account for more than 10% of the company's main business income. According to the 2022 Q1-Q4 Zhongkang CHM data, the market share of Dafuxin minoxidil liniment OTC reached 42.34%, ranking second in sales volume. Li Anping, chairman of Zhendong Pharmaceutical, once said that the company's Dafuxin minoxidil liniment currently ranks first in the country in sales in the field of hair shaping, with a growth rate of over 50% for three consecutive years. Zhendong will take "skin medication" as its core and strive to create "the first brand of dermatology medication".
According to the investor relations activity record form disclosed by the company, some investors asked questions about "the company sold its main assets, its performance is not satisfactory, and what countermeasures are planned." Zhendong Pharmaceutical once responded that the company's strategic positioning is "marketing innovation" "The enterprise aims at the field of "dermatology medicine, tumor traditional Chinese medicine, traditional Chinese medicinal materials and raw materials", and lays out its layout from raw materials to preparations, from imitation to innovation, improves the product pipeline, and forms advantages in the field; Chinese medicinal materials are bred, planted from seeds and seedlings, From processing and warehousing to establishing and improving quality standards, we create a high-standard integrated industrial chain.
As of the close of trading at noon on January 4, Zhendong Pharmaceutical’s share price was reported at 6.48 yuan, down 1.97%, with a total market value of 6.658 billion yuan.
Source: Daily Economic News is compiled from China Trial Publicity Network, Beijing Business Daily, Meijing.com, Brokerage China, Jiemian News, public information, etc.
-
-
-
-
-
-
-
-
-
-